Reconciled ClinicalTrials.gov v2 Protocol Specification
| Protocol Field | Verified Registry Value |
|---|---|
| NCT Identifier | NCT03867097 |
| Consolidated Lead Sponsor | Civi Biopharma |
| Therapeutic Condition Cohort | Immunology, Rheumatology, and Dermatology |
| Clinical Trial Phase | Phase II |
| Overall Recruitment Status | COMPLETED |
| Registered Enrollment | 34 participants (ACTUAL) |
| Registered Start Date | 2019-03-07 |
| WhyStopped Classification | Not Stopped |
Named U.S. Hospital Clinical Research Sites
| Hospital Research Site | Location | Site Profile |
|---|---|---|
| Stanford Health Care and Stanford Cancer Institute | Stanford, CA | Open Hospital Dossier -> |
| UCSF Medical Center and Helen Diller Cancer Center | San Francisco, CA | Open Hospital Dossier -> |
| Johns Hopkins Hospital and Kimmel Cancer Center | Baltimore, MD | Open Hospital Dossier -> |
| University of Michigan Rogel Cancer Center | Ann Arbor, MI | Open Hospital Dossier -> |
Search related sites and sponsors in the Interactive Directory, explore Immunology, Rheumatology, and Dermatology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.